Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of low-dose cyclosporine in association with everolimus to minimize renal dysfunction in heart transplant recipients.

Next Previous
X
Search
Trial Profile

Safety and efficacy of low-dose cyclosporine in association with everolimus to minimize renal dysfunction in heart transplant recipients.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms SHIRAKISS

    • Most Recent Events

    • 16 Apr 2011 2-year results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 27 Jan 2010 Results reported in Transplantation.
    • 12 May 2009 Additional lead trial centre Alma Mater Studiorum University of Bologna identified, primary endpoint identified as GFR as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top